Michel Goossens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Michel Goossens has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Catherine Matheron
Laboratoire d'Hématologie, Hôpital Henri Mondor, Créteil, France
1 shared publicationClarisse Baumann
U.F. de génétique clinique, hôpital Robert-Debré, Paris, France
1 shared publicationDavid Mowat
Department of Medical Genetics and Pediatrics, Sydney Children's Hospital, University of New South Wales, Sydney, Australia
1 shared publicationEmmanuelle Simon
Committee for Evaluation and Diffusion of Innovative Technologies (CEDIT), Assistance‐Publique Hôpitaux de Paris (AP‐HP), Paris, France
1 shared publication- Huw Dorkins
St Peter's College, University of Oxford, Oxford, UK
1 shared publication Ishwar Verma
Department of Genetic Medicine, Sir Ganga Ram Hospital, Rajender Nagar, New Delhi, India
1 shared publication
Latest Publications
- 30 April 2004
- Published by Hindawi Limited in Human Mutation
- Vol. 23 (6) , 621-628
An improved electronic microarray-based diagnostic assay for identification ofMEFV mutations
Recent technological advances, such as DNA chip devices that allow automated, high‐throughput genotyping, promise to considerably improve the detection capability of single‐nucleotide polymorphisms (SNPs) in clinically relevant genes. We used the NanoChip® Molecular Biology Workstation (Nanogen, www.nanogen.com) and recently introduced microelectronic array technology to develop a detection method for the more frequent mutations involved in familial Mediterranean fever (FMF), an autosomal recessive disease that affects several ethnic groups in the Mediterranean population, whose early diagnosis is crucial if severe complications are to be prevented. We adapted the previously described Nanogen procedures to FMF mutation analysis, introducing modifications that notably improve the technique. First, as the original procedure makes use of costly dye‐tagged reporter sequences, we devised a universal reporter strategy, which was first evaluated and validated on the robust, previously established factor V Leiden and factor II (prothrombin) NanoChip diagnostic assays. FMF (MEFV), factor V (F5), and factor II (F2) genotypes identified using this improved system were totally concordant with results of other genotyping methods (denaturing gradient gel electrophoresis [DGGE], SSCP, and RFLP analysis). Second, we showed that the target sequences loaded on the NanoChip cartridges can be rehybridized several times in a highly reproducible manner, allowing sequential analysis of mutations. Thus, we devised a strategy that allows us to monitor the possible interference of additional mutations or SNPs at probe or stabilizer sequences. Finally, a comparative cost per sample analysis demonstrates that the accurate and reproducible FMF mutation detection assay we developed can be readily implemented in the clinical laboratory setting at reasonable expense. Hum Mutat 23:621–628, 2004.
- 30 April 2004
- Published by Hindawi Limited in Human Mutation
- Vol. 23 (6) , 621-628
An improved electronic microarray-based diagnostic assay for identification ofMEFV mutations
Recent technological advances, such as DNA chip devices that allow automated, high‐throughput genotyping, promise to considerably improve the detection capability of single‐nucleotide polymorphisms (SNPs) in clinically relevant genes. We used the NanoChip® Molecular Biology Workstation (Nanogen, www.nanogen.com) and recently introduced microelectronic array technology to develop a detection method for the more frequent mutations involved in familial Mediterranean fever (FMF), an autosomal recessive disease that affects several ethnic groups in the Mediterranean population, whose early diagnosis is crucial if severe complications are to be prevented. We adapted the previously described Nanogen procedures to FMF mutation analysis, introducing modifications that notably improve the technique. First, as the original procedure makes use of costly dye‐tagged reporter sequences, we devised a universal reporter strategy, which was first evaluated and validated on the robust, previously established factor V Leiden and factor II (prothrombin) NanoChip diagnostic assays. FMF (MEFV), factor V (F5), and factor II (F2) genotypes identified using this improved system were totally concordant with results of other genotyping methods (denaturing gradient gel electrophoresis [DGGE], SSCP, and RFLP analysis). Second, we showed that the target sequences loaded on the NanoChip cartridges can be rehybridized several times in a highly reproducible manner, allowing sequential analysis of mutations. Thus, we devised a strategy that allows us to monitor the possible interference of additional mutations or SNPs at probe or stabilizer sequences. Finally, a comparative cost per sample analysis demonstrates that the accurate and reproducible FMF mutation detection assay we developed can be readily implemented in the clinical laboratory setting at reasonable expense. Hum Mutat 23:621–628, 2004.
- 6 July 2002
- Published by Springer Nature in Human Genetics
- Vol. 111 (2) , 198-206
SOX10 mutations in chronic intestinal pseudo-obstruction suggest a complex physiopathological mechanism
The type IV Waardenburg syndrome (WS4), also referred to as Shah-Waardenburg syndrome or Waardenburg-Hirschsprung disease, is characterised by the association of Waardenburg features (WS, depigmentation and deafness) and the absence of enteric ganglia in the distal part of the intestine (Hirschsprung disease). Mutations in the EDN3, EDNRB, and SOX10 genes have been reported in this syndrome. Recently, a new SOX10 mutation was observed in a girl with a neural crest disorder without evidence of depigmentation, but with severe constipation due to a chronic intestinal pseudo-obstruction and persistence of enteric ganglia. To refine the nosology of WS, we studied patients with typical WS4 (including Hirschsprung disease) or with WS and intestinal pseudo-obstruction. We found three SOX10 mutations, one EDNRB and one EDN3 mutations in patients presenting with the classical form of WS4, and two SOX10 mutations in patients displaying chronic intestinal pseudo-obstruction and WS features. These results show that chronic intestinal pseudo-obstruction may be a manifestation associated with WS, and indicate that aganglionosis is not the only mechanism underlying the intestinal dysfunction of patients with SOX10 mutations.
- 6 July 2002
- Published by Springer Nature in Human Genetics
- Vol. 111 (2) , 198-206
SOX10 mutations in chronic intestinal pseudo-obstruction suggest a complex physiopathological mechanism
The type IV Waardenburg syndrome (WS4), also referred to as Shah-Waardenburg syndrome or Waardenburg-Hirschsprung disease, is characterised by the association of Waardenburg features (WS, depigmentation and deafness) and the absence of enteric ganglia in the distal part of the intestine (Hirschsprung disease). Mutations in the EDN3, EDNRB, and SOX10 genes have been reported in this syndrome. Recently, a new SOX10 mutation was observed in a girl with a neural crest disorder without evidence of depigmentation, but with severe constipation due to a chronic intestinal pseudo-obstruction and persistence of enteric ganglia. To refine the nosology of WS, we studied patients with typical WS4 (including Hirschsprung disease) or with WS and intestinal pseudo-obstruction. We found three SOX10 mutations, one EDNRB and one EDN3 mutations in patients presenting with the classical form of WS4, and two SOX10 mutations in patients displaying chronic intestinal pseudo-obstruction and WS features. These results show that chronic intestinal pseudo-obstruction may be a manifestation associated with WS, and indicate that aganglionosis is not the only mechanism underlying the intestinal dysfunction of patients with SOX10 mutations.